Director/PDMR Shareholding
Updated : 15:46
30 November 2020
ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding
The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
The Company has been informed that Shares held by Mr Karim Bitar, Chief Executive Officer and a PDMR, were transferred into nominee accounts for nil consideration. The transfer of Shares into each nominee account completed as follows:
1. 616,234 Shares on 25 November 2020
2. 989,830 Shares on 26 November 2020
No change to the number of Shares beneficially held by Mr Bitar has occurred in connection with the transfer of Shares and Mr Bitar remains interested in the 1,606,064 Shares.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||
a) | Name | Karim Bitar | ||
2 | Reason for the notification | |||
a) | Position/Status | Chief Executive Officer | ||
b) | Initial notification/Amendment | Initial notification | ||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
a) | Name | ConvaTec Group Plc | ||
b) | LEI | 213800LS272L4FIDOH92 | ||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 10p each in ConvaTec Group Plc ("Shares") GB00BD3VFW73 | ||
b) | Nature of the transaction | Transfer of 616,234 Shares to a nominee account. | ||
c) | Price(s) and volume(s) | Price(s) N/A
| Volume(s) 616,234 | |
d) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||
e) | Date of the transaction | 25 November 2020 | ||
f) | Place of the transaction | Outside of a trading venue | ||
|
|
|
|
|
1 | Details of the person discharging managerial responsibilities/person closely associated | |||
a) | Name | Karim Bitar | ||
2 | Reason for the notification | |||
a) | Position/Status | Chief Executive Officer | ||
b) | Initial notification/Amendment | Initial notification | ||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
a) | Name | ConvaTec Group Plc | ||
b) | LEI | 213800LS272L4FIDOH92 | ||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 10p each in ConvaTec Group Plc ("Shares") GB00BD3VFW73 | ||
b) | Nature of the transaction | Transfer of 989,830 Shares to a nominee account | ||
c) | Price(s) and volume(s) | Price(s) N/A
| Volume(s) 989,830 | |
d) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||
e) | Date of the transaction | 26 November 2020 | ||
f) | Place of the transaction | Outside of a trading venue | ||
|
|
|
|
|
|
|
|
|
|
Enquiries
Analysts and Investors
Kate Postans, VP Investor Relations &
Corporate Communications, ConvaTec, +44 (0)7826 447807
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.